H2R Tuesday, 11/19/19 03:47:26 PM Re: None Post # of 4751 SOS on ATRS: Projections https://smithonstocks.com/antares-pharmaceuticals-projecting-very-strong-growth-in-xyosted-sales-for-2020-2021-and-2022-atrs-buy-3-89/ Quote: Key Points In my sales and earnings model for 2020, I will be using a working estimate of $53.6 million for sales of Xyosted in 2020. My working estimate is lower than two alternative scenarios laid out in this report. In Scenario 1, I arrive at a sales estimate of $70.3 million for 2020 and in scenario 2 it is $63.1 million. My intuition is that the assumptions underlying both Scenarios 1 and 2 are conservative. However, we are at a very early stage in the launch and have only sketchy data so that I have “haircut” my working estimate to $53.6 million. Quite recently, the consensus Street estimate for 2020 sales was $45 to $50 million. My working estimate for 2021 sales is $85.8 million and for 2022 is $115.8 million.